What strict compliance costs

The previous articles in this series describe what the law requires and what FDA's enforcement record shows. This one is about money. Strict research-use-only compliance is not free, and it is not a marketing angle that can be added to an otherwise unchanged business. It removes revenue, adds cost and slows growth. Understanding why is the clearest way to understand why so few sellers do it.

The market a compliant seller declines

The starting point is uncomfortable. For many of the peptides most often sold online, public demand is overwhelmingly demand for use in people. FDA's own compliance office describes the pressure directly:

The unprecedented demand for GLP-1 medications, including semaglutide and tirzepatide, has led to illegal activity outside of the legitimate drug supply chain, which poses significant public health concerns.

A seller that is genuinely selling for laboratory research is, by definition, declining that demand. Its market is laboratories, institutions and qualified researchers: a real market, but a small fraction of the traffic that arrives at a peptide store. Every compliance decision below follows from accepting that.

Strict compliance does not trim the edges of the market. It removes most of it, on purpose.

What is given up

Each of the common practices in the previous article exists because it earns money. Declining them has a direct commercial effect.

Common practice, compliant practice, and the commercial effect of the difference

Lever	Common practice	Compliant practice	Commercial effect
Product copy	Benefits and effects, often borrowed from clinical trials	Chemistry, analytical data and published in vitro work only	Lower conversion; copy that sells to researchers, not to the public
Search and content	Pages and articles built around effect-related search terms	No content aimed at use in people	The largest sources of search traffic are given up
Product names	Names that echo approved medicines	Chemical or established research names	Fewer buyers recognise the product
Accompanying products	Solvents, kits and equipment sold alongside	Nothing sold that points to use in people	Smaller baskets; customers buy elsewhere
Tools	Preparation calculators and usage guides	None	Lost traffic and repeat visits
Promotion	Affiliates, influencers and discount-code partners	No representatives whose statements the seller does not control	The fastest acquisition channel is closed
Social proof	Reviews and testimonials describing personal use	None that describe use in people	Less persuasive pages
Customers	Anyone with a card	Verified, qualified buyers who accept recorded terms	Checkout friction; many visitors cannot buy at all
Customer service	Answers to use questions	Refusal, a record, and declined sales where intent is clear	Lost orders and unhappy enquirers
Catalogue	Whatever is in demand	Only what can be credibly sold for research, presented as research material	The most-searched products may be restricted or not sold

None of these effects is small, and they compound. Fewer visitors arrive; fewer of those can buy; those who buy spend less; and the channels that would normally make up the shortfall are closed.

What is taken on

At the same time, a compliant seller carries costs that a non-compliant one does not:

• Buyer qualification. Collecting and checking who the buyer is, what organisation they represent and what their research is, and keeping the record.
• Recorded agreements. Terms that each buyer accepts, stored with each order, so that the seller can show what was agreed and when.
• Content review. Every page, product description, email template, support reply and announcement reviewed against intended-use rules, before publication and again whenever the rules or the record change.
• Catalogue governance. Decisions about what to sell, what to call it, how to group it and what to sell beside it, made as compliance decisions, not merchandising ones.
• Analytical documentation. Testing for every lot, with certificates that match the material actually shipped.
• Traceability and records. The ability to show, for any unit, which lot it came from, who bought it and on what terms.
• Training and discipline. Staff who decline questions consistently, every time, including when the customer is friendly and the order is large.
• Legal review. Advice that is paid for in advance, not after a letter arrives.

Why the market drifts the other way

The economics explain the pattern in the enforcement record. The costs of compliance are immediate, certain and visible on every day's sales. The costs of non-compliance arrive later, if at all, and a seller who stretches the rules wins customers from one who does not. In a market where most competitors make the same choices, each one can tell itself that it is no worse than the rest.

That reasoning depends on enforcement being rare and mild. The public record from 2025 and 2026 does not support either assumption: letters arrive in sweeps, they follow reviews of ordinary websites, and the toolkit behind them runs from import detention to federal prison.

It also depends on the agency's current interpretation staying where it is. FDA's warning letters are, by its own description, informal and advisory: they show how the agency reads the law today, not how it must read it tomorrow. Interpretation and enforcement priorities can tighten as well as relax. A business whose model only works under today's reading is betting on the one variable it does not control.

The asymmetry

The two sides of the calculation are not alike. Compliance costs revenue. Non-compliance risks the business, its supply, its payment relationships and, under the responsible corporate officer doctrine, the liberty of the people who run it.

One side of the ledger is a smaller business. The other side is no business at all.

A business model, not a disclaimer

This is why research-use-only compliance cannot be bolted on. A business built on the demand described above, with its traffic, its tools, its partners and its customers, cannot become compliant by changing its labels: removing the practices removes the business. Compliance has to be chosen at the start and designed in: a smaller market, served deliberately, with the systems to prove it.

It is a choice few sellers make, because it is expensive. It is also the only one that survives the scrutiny described in this series. The final article looks at how that scrutiny is likely to develop, and what it will demand of the platforms that remain.

Frequently asked questions

Is it possible to be compliant and profitable?

Yes, but as a different business: one that serves research buyers, accepts a smaller market and carries the cost of proving what it does. It is not the same business with better labels.

Why not keep the profitable practices and accept the risk?

Because the risk is not a fine. The enforcement record includes seizure, injunction, import detention and criminal sentences, and individuals can be held responsible.

Does turning away customers really matter?

Yes. Under 21 CFR 201.128, the circumstances of distribution, including to whom a product is sold and what the seller knows about their intentions, are evidence of intended use.

Sources & Further Reading

1. 21 CFR 201.128, Meaning of "intended uses".
2. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Compliance. Annual Report 2025. April 2026.
3. Federal Food, Drug, and Cosmetic Act §§ 301, 303; 21 U.S.C. §§ 331, 333.
4. United States v. Park, 421 U.S. 658 (1975).
5. Food and Drug Administration, CDER. Warning letters to online peptide sellers dated March 31, 2026 and August 24, 2026, as listed in the second article of this series.
6. United States Attorney's Office, Northern District of Indiana. United States v. Matthew Kawa; sentencing of July 30, 2026.
7. Food and Drug Administration. Regulatory Procedures Manual, Chapter 4: Advisory Actions (Warning Letters and Untitled Letters).